Award details

Creating an effective and non toxic blood substitute

Reference	BB/L004232/1
Principal Investigator / Supervisor	Professor Christopher Cooper
Co-Investigators / Co-Supervisors	Dr Brandon Reeder
Institution	University of Essex
Department	Biological Sciences
Funding type	Research
Value (£)	635,140
Status	Completed
Type	Research Grant
Start date	31/12/2013
End date	30/09/2016
Duration	33 months

Abstract

unavailable

Summary

Blood transfusion is a life saving technology. However red blood cells: have a limited shelf life; need blood group typing; cannot be used in immune compromised individuals; are not available at the scenes of accidents, battlefields or major emergencies; and are susceptible to viral contamination. Blood transfusion is big business. In the UK alone two million units of blood are transfused annually at a cost of > £200 million. The addressable future global market value is $10Bn. A number of companies have attempted to develop alternatives to transfusions based on modifications of the red cell oxygen transport protein hemoglobin. However, toxic side effects have been seen in clinical trials. Arising out of BBSRC funded grants, the University of Essex has engineered novel hemoglobin molecules designed to reduce cell damage. A patent is pending. The purpose of this grant is to undertake lead optimisation, product development and in vivo testing on this next generation blood substitute.

Committee	Not funded via Committee
Research Topics	Pharmaceuticals
Research Priority	X – Research Priority information not available
Research Initiative	Follow-On Fund Super (SuperFOF) [2012-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search